$AADI
Aadi Bioscience, Inc.

2017 Q2 Form 10-Q Financial Statement

#000156459017017234 Filed on August 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.410M $1.470M
YoY Change 63.95%
% of Gross Profit
Research & Development $3.169M $2.904M
YoY Change 9.15%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $5.584M $4.377M
YoY Change 27.56%
Operating Profit -$5.584M -$4.377M
YoY Change 27.56%
Interest Expense $52.32K -$88.78K
YoY Change -158.93%
% of Operating Profit
Other Income/Expense, Net $63.56K -$7.829K
YoY Change -911.79%
Pretax Income -$5.520M -$4.390M
YoY Change 25.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.520M -$4.385M
YoY Change 25.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.06 -$2.88
COMMON SHARES
Basic Shares Outstanding 27.08M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.90M
YoY Change
Cash & Equivalents $28.85M $1.603M
Short-Term Investments $100.0K
Other Short-Term Assets $431.2K
YoY Change
Inventory
Prepaid Expenses $311.1K
Receivables $4.264K
Other Receivables $0.00
Total Short-Term Assets $29.64M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $129.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $150.0K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $29.64M
Total Long-Term Assets $150.0K
Total Assets $29.79M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $782.2K
YoY Change
Accrued Expenses $1.100M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.857M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.857M
Total Long-Term Liabilities $0.00
Total Liabilities $1.900M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$97.68M
YoY Change
Common Stock $125.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.94M
YoY Change
Total Liabilities & Shareholders Equity $29.79M
YoY Change

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$5.520M -$4.385M
YoY Change 25.88%
Depreciation, Depletion And Amortization $20.00K $20.00K
YoY Change 0.0%
Cash From Operating Activities -$6.320M -$3.980M
YoY Change 58.79%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 4.420M
YoY Change -99.1%
NET CHANGE
Cash From Operating Activities -6.320M -3.980M
Cash From Investing Activities -10.00K 0.000
Cash From Financing Activities 40.00K 4.420M
Net Change In Cash -6.290M 440.0K
YoY Change -1529.55%
FREE CASH FLOW
Cash From Operating Activities -$6.320M -$3.980M
Capital Expenditures $10.00K $0.00
Free Cash Flow -$6.330M -$3.980M
YoY Change 59.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
63555
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2903564
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4377433
us-gaap Operating Income Loss
OperatingIncomeLoss
-10343447
CY2017Q2 arpo Grant Income
GrantIncome
11239
CY2016Q2 arpo Grant Income
GrantIncome
80954
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
52316
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-88783
CY2016Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1028121
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
353434
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
209038
CY2016Q4 us-gaap Assets Current
AssetsCurrent
2226323
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149595
CY2016Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
12386647
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
2707
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
125612938
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97678060
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
27937585
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29794402
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27070038
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4157
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
124
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86218753
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-86218629
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2396878
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
50000
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4264
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3169115
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-5520307
CY2016Q2 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
224224
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
17440436
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1240925
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1240925
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
997
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27070038
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
943297
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5189159
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26895164
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
823097
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
74701187
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
13447934
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37163390
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36101
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
59277
us-gaap Paid In Kind Interest
PaidInKindInterest
204929
us-gaap Paid In Kind Interest
PaidInKindInterest
89962
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
107
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-113943
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
179743
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-259938
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-130711
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-71261
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10252055
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7845346
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113297
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6547
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-113297
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4536531
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
138312
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40247775
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37496845
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27238243
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5144211
arpo Accretion Of Preferred Stock To Redemption Value
AccretionOfPreferredStockToRedemptionValue
943297
CY2017Q2 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
302106
CY2017Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
106686
CY2017Q2 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
354995
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53972
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Share Based Compensation
ShareBasedCompensation
119550
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7800
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
50000
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
73757890
us-gaap Operating Income Loss
OperatingIncomeLoss
-8582876
us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
224224
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2043492
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11459307
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10399229
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.33
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266909
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3084385
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4417188
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3541455
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1602756
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
74701187
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
13447934
arpo Accretion Of Preferred Stock To Redemption Value
AccretionOfPreferredStockToRedemptionValue
2043492
arpo Extinguishment Of Preferred Stock
ExtinguishmentOfPreferredStock
224224
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: fair value of the Company&#8217;s common stock and other equity instruments, accrued expenses, and income taxes. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes significant estimates and assumptions in determining the fair value of its common stock and other equity instruments. The Company granted stock options at exercise prices not less than the fair value of its common stock, as determined by the Board of Directors contemporaneously at the date such grants were made. The Board of Directors has determined the estimated fair value of the Company&#8217;s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of common and preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time, and, for periods prior to the Offering, the likelihood of achieving a liquidity event, such as a public offering or sale of the Company. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font>, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of redeemable convertible preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time, and, at December&#160;31, 2016, a probability analysis of various liquidity events under differing scenarios, including both a potential public trading scenario and potential sale scenario. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock and other equity instruments at each valuation date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s results can also be affected by economic, political, legislative, regulatory, and legal actions. Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, government fiscal policies, and changes in the prices of research studies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities and carries various levels of insurance, the Company could be affected by civil, criminal, regulatory or administrative actions, claims, or proceedings. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Off-Balance Sheet Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and short-term investments are the only financial instruments that potentially subject the Company to concentrations of credit risk. At June 30, 2017 and December&#160;31, 2016, all the Company&#8217;s cash was deposited in accounts at two principal financial institutions. The Company maintains its cash and cash equivalents and short-term investments with a high-quality, accredited financial institution and, accordingly, such funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. </p></div>
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q4 arpo Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1135608
CY2017Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
256889
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
483442
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
52835
CY2016Q4 arpo Accrued Project Costs Current
AccruedProjectCostsCurrent
541158
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2017Q2 arpo Number Of Shares Of Common Stock In Lock Up Agreements
NumberOfSharesOfCommonStockInLockUpAgreements
18900000
arpo Restricted Period For Shares Of Common Stock In Lock Up Agreements
RestrictedPeriodForSharesOfCommonStockInLockUpAgreements
P9M
arpo Restricted Percentage Of Common Stock For Holders Of Specified Shares
RestrictedPercentageOfCommonStockForHoldersOfSpecifiedShares
0.80
CY2017Q2 arpo Number Of Shares Of Common Stockholders With Specified Percentage Restriction
NumberOfSharesOfCommonStockholdersWithSpecifiedPercentageRestriction
915000
arpo Period Agreed By Common Stockholder Not To Effect Short Sale After Merger
PeriodAgreedByCommonStockholderNotToEffectShortSaleAfterMerger
P12M
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
317562
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.00
CY2017Q2 arpo Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P3Y
arpo Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
2020-03-15
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
arpo Redeemable Convertible Preferred Stock Voting Rights
RedeemableConvertiblePreferredStockVotingRights
The holders of redeemable convertible preferred stock were entitled to the number of votes equal to the number of whole shares of Aerpio common stock into which the shares of redeemable convertible preferred stock were convertible. Except as provided by law or otherwise, the holders of redeemable convertible preferred stock voted together with the holders of Aerpio common stock as a single class. Certain significant actions required approval by at least 50% of the holders of redeemable convertible preferred stock voting as a single class on an as converted basis.
arpo Redeemable Convertible Preferred Stock Conversion Percentage
RedeemableConvertiblePreferredStockConversionPercentage
1
CY2016Q1 arpo Redeemable Convertible Preferred Stock Conversion Percentage
RedeemableConvertiblePreferredStockConversionPercentage
3
arpo Redeemable Convertible Preferred Stock Redemption Date
RedeemableConvertiblePreferredStockRedemptionDate
2017-07-31
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
927592
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25729
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2901
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
898962
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
231733
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
667229
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.70
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.11
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.70
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.80
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.67
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M28D
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y6M0D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1030217
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
742130
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2221319
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
226405
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0139
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0139
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7800
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
arpo Area Of Lease Property
AreaOfLeaseProperty
7580
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-06-30
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
51153
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
59924
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
102442
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
108104
CY2016Q2 arpo Lease Allowances For Tenant Improvements
LeaseAllowancesForTenantImprovements
0
arpo Lease Allowances For Tenant Improvements
LeaseAllowancesForTenantImprovements
46390
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
46372
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
105735
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
52757
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
52978
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ARPO
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 us-gaap Other Assets Current
OtherAssetsCurrent
431151
CY2017Q2 us-gaap Assets Current
AssetsCurrent
29644416
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
129026
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20960
CY2017Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20960
CY2016Q4 us-gaap Assets
Assets
2396878
CY2017Q2 us-gaap Assets
Assets
29794402
CY2017Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1856817
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1856817
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2470970
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14857617
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311064
dei Amendment Flag
AmendmentFlag
false
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28847937
dei Entity Central Index Key
EntityCentralIndexKey
0001422142
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1609694
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27070038
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16313324
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
780152
us-gaap Share Based Compensation
ShareBasedCompensation
266909
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
111524
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2963449
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M14D
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
200468
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
782169
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57459
us-gaap Operating Expenses
OperatingExpenses
8582876
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
5583862
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4918748
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5583862
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2689754
us-gaap Operating Expenses
OperatingExpenses
10343447
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
4377433
us-gaap Depreciation
Depreciation
37991
us-gaap Share Based Compensation
ShareBasedCompensation
244765
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
75561
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6547
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
36101
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18969
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
297354
us-gaap Depreciation
Depreciation
27117
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 arpo Capital Stock Conversion Basis Ratio
CapitalStockConversionBasisRatio
2.3336572
arpo Grant Income
GrantIncome
89624
arpo Grant Income
GrantIncome
46896
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-219459
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-87706
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7829
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-172563
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2915
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-4385262
us-gaap Net Income Loss
NetIncomeLoss
-10516010
us-gaap Net Income Loss
NetIncomeLoss
-8579961
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5520307
dei Entity Registrant Name
EntityRegistrantName
Aerpio Pharmaceuticals, Inc.
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-17-017234-index-headers.html Edgar Link pending
0001564590-17-017234-index.html Edgar Link pending
0001564590-17-017234.txt Edgar Link pending
0001564590-17-017234-xbrl.zip Edgar Link pending
arpo-10q_20170630.htm Edgar Link pending
arpo-20170630.xml Edgar Link completed
arpo-20170630.xsd Edgar Link pending
arpo-20170630_cal.xml Edgar Link unprocessable
arpo-20170630_def.xml Edgar Link unprocessable
arpo-20170630_lab.xml Edgar Link unprocessable
arpo-20170630_pre.xml Edgar Link unprocessable
arpo-ex311_9.htm Edgar Link pending
arpo-ex312_8.htm Edgar Link pending
arpo-ex321_6.htm Edgar Link pending
arpo-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending